| 1 |
35163469 | Teriflunomide Preserves Neuronal Activity and Protects Mitochondria in Brain Slices Exposed to Oxidative Stress. | 2022 Jan 28 |
1 |
| 2 |
32426367 | Teriflunomide Does Not Change Dynamics of Nadph Oxidase Activation and Neuronal Dysfunction During Neuroinflammation. | 2020 |
2 |
| 3 |
32850106 | Teriflunomide preserves peripheral nerve mitochondria from oxidative stress-mediated alterations. | 2020 |
1 |
| 4 |
30417265 | Spatial and molecular changes of mouse brain metabolism in response to immunomodulatory treatment with teriflunomide as visualized by MALDI-MSI. | 2019 Jan |
2 |
| 5 |
28435533 | Discovery of Antimalarial Azetidine-2-carbonitriles That Inhibit P. falciparum Dihydroorotate Dehydrogenase. | 2017 Apr 13 |
1 |
| 6 |
27391060 | Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells. | 2016 Aug 2 |
2 |
| 7 |
27597161 | Discovery of a new structural class of competitive hDHODH inhibitors with in vitro and in vivo anti-inflammatory, immunosuppressive effects. | 2016 Nov 15 |
1 |
| 8 |
23355744 | Disruption of uridine homeostasis links liver pyrimidine metabolism to lipid accumulation. | 2013 Apr |
2 |
| 9 |
23977077 | Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo. | 2013 |
2 |
| 10 |
22692683 | Miller (Genee-Wiedemann) syndrome represents a clinically and biochemically distinct subgroup of postaxial acrofacial dysostosis associated with partial deficiency of DHODH. | 2012 Sep 15 |
4 |
| 11 |
20310011 | 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. | 2010 Oct |
2 |
| 12 |
18932012 | Converting NADH to NAD+ by nicotinamide nucleotide transhydrogenase as a novel strategy against mitochondrial pathologies during aging. | 2009 Aug |
1 |
| 13 |
11248707 | Recombinant expression of N-terminal truncated mutants of the membrane bound mouse, rat and human flavoenzyme dihydroorotate dehydrogenase. A versatile tool to rate inhibitor effects? | 2001 Mar |
1 |
| 14 |
9353408 | Control of lymphoproliferative and autoimmune disease in MRL-lpr/lpr mice by brequinar sodium: mechanisms of action. | 1997 Nov |
1 |
| 15 |
7673235 | Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. | 1995 Sep 22 |
1 |
| 16 |
2153375 | Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer. | 1990 Jan 1 |
2 |
| 17 |
2164443 | In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients. | 1990 Aug 1 |
1 |
| 18 |
2822596 | Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390). | 1987 |
1 |
| 19 |
3019518 | Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis. | 1986 Oct |
1 |
| 20 |
6249586 | On the role of dihydroorotate dehydrogenase in growth cessation of Ehrlich ascites tumor cells cultured under oxygen deficiency. | 1980 |
1 |
| 21 |
35542 | Effect of 6-azauridine on de novo pyrimidine biosynthesis in cultured Ehrlich ascites cells. Orotate inhibition of dihydroorotase and dihydroorotate dehydrogenase. | 1979 Jun 10 |
1 |